Q5.SCOPING QUESTION: In individuals with psychotic disorders (including schizophrenia) who require long-term antipsychotic treatment, what is the safety and role of depot antipsychotic medication?
Q7: In individuals with bipolar mania, are a) antipsychotics, b) mood stabilizers (lithium carbonate, valproate, and carbamazepine) effective and safe
Q8. SCOPING QUESTION: In people with bipolar disorders who require maintenance treatment, are a) antipsychotics or b) mood stabilizers (lithium, valproate or carbamazepine) effective and safe?
Q10: In individuals with psychotic disorders (including schizophrenia) and bipolar disorders are psychoeducation, family interventions and cognitive-behavioural therapy feasible and effective?
Accessed: 21.03.2019
mhGAP Training Manual for the mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings – version 2.0 (for field testing)
The WHO Global Burden of Disease (GBD) study measures the burden of
disease using the disability-adjusted life year metric (DALY). The DALY metric
was developed to assess the burden of disease consistently across diseases,
risk factors and region...s. A consistent and comparative description of the burden
of diseases and injuries and the risk factors that cause them is important as it
can inform health decision-making and health care planning.
more
It is recommended that egg based quadrivalent vaccines for use in the 2019-2020 northern hemisphere influenza season contain the following:
an A/Brisbane/02/2018 (H1N1)pdm09-like virus;
an A(H3N2) virus to be announced on 21 March 2019*;
a B/Colorado/06/2017-like virus (B/Victoria/...2/87 lineage); and
a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).
It is recommended that the influenza B virus component of trivalent vaccines for use in the 2019-2020 northern hemisphere influenza season be a B/Colorado/06/2017-like virus of the B/Victoria/2/87-lineage.
* In light of recent changes in the proportions of genetically and antigenically diverse A(H3N2) viruses, the recommendation for the A(H3N2) component has been postponed.
more
Інформаційний матеріал по темі депресія
плакат
Информационный материал по теме депрессия
mhGAP Training Manual for the mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings – version 2.0 (for field testing)
Accessed 06.03.2019
Q 10: In adults and children with epilepsy, which psychological interventions used as adjunctive therapies with antiepileptic drugs when compared to placebo/comparator produce benefits/harm in specified outcomes?
Q9. In adults and children with convulsive epilepsy in remission, when should treatment be discontinued?
Q6: What is the added advantage of doing neuroimaging in people with convulsive epilepsy in non-specialist settings in low and middle income countries?
Q3: Can febrile seizures (simple or complex) be managed at first or second level care by non-specialist health care providers in low and middle income country settings? What is the role of diagnostic tests in the management of febrile seizures by no...n-specialists in low and middle income settings? For prophylaxis to prevent recurrence of simple or complex febrile seizures, which of the pharmacological interventions when compared with placebo/comparator produce benefit/harm in specified outcomes?
- continuous anticonvulsant therapy - intermittent anticonvulsant therapy - intermittent antipyretic treatment
more
Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?
Q5: What is the added advantage of doing an electroencephalography (EEG) in people with convulsive epilepsy in non- specialist settings in low and middle income countries?
[Updated 2015]
Scoping Question: In adults with acute convulsive seizures in first-level care or in the community (when no IV access is available), which antiepileptic medications produce benefits and/or harm when compared to comparator?
Доклад Секретариата по теме Деменция
В июне 2016 г. в решении EB139(1) Исполнительный комитет обратился к Генеральному директору с просьбой разработать при всестороннем участии государств-членов и в сотруд...ничестве с другими соответствующими заинтересованными сторонами проект Глобального плана действий сектора общественного здравоохранения по реагированию на деменцию с четкими целями и задачами и представить его на рассмотрение Семидесятой сессии Всемирной ассамблеи здравоохранения через Исполнительный комитет на его Сто сороковой сессии. В Приложении к настоящему докладу содержится проект плана действий, который охватывает период 2017-2025 годов.
more